A bulk of studies suggest the overexpression of IGF2BP1 and IGF2BP3 facilitate the progress of lung cancer, and relate to the prognosis of LUAD patients (Beljan Perak et al., 2012; Gong et al., 2016; Guo et al., 2021; Huang et al., 2019; Kato et al., 2007; Li & Zhan, 2020; Li et al., 2020b; Mizutani et al., 2016; Müller et al., 2019; Ohdaira et al., 2012; Wang, He & Ma, 2020; Xueqing et al., 2020; Zhang et al., 2020a). This evidence concerns the gene IGF2BP3 and lung cancer.